vs
Side-by-side financial comparison of Andersons, Inc. (ANDE) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
Andersons, Inc. is the larger business by last-quarter revenue ($329.5M vs $185.2M, roughly 1.8× AMICUS THERAPEUTICS, INC.). Andersons, Inc. runs the higher net margin — 20.5% vs 0.9%, a 19.6% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs -2.4%). AMICUS THERAPEUTICS, INC. produced more free cash flow last quarter ($16.0M vs $-77.1M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs -1.8%).
The Andersons, Inc. is an American agribusiness established in 1947, that began as Andersons Truck Terminal (ATT) in the 1940s for the grain industry, headquartered in Maumee, Ohio. It is a diversified company rooted in agriculture that conducts business in the commodity merchandising, renewables, and plant nutrient sectors.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
ANDE vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $329.5M | $185.2M |
| Net Profit | $67.4M | $1.7M |
| Gross Margin | 70.3% | 85.7% |
| Operating Margin | 26.6% | 8.6% |
| Net Margin | 20.5% | 0.9% |
| Revenue YoY | -2.4% | 23.7% |
| Net Profit YoY | 49.6% | -88.5% |
| EPS (diluted) | — | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $329.5M | $185.2M | ||
| Q3 25 | $295.8M | $169.1M | ||
| Q2 25 | $535.0M | $154.7M | ||
| Q1 25 | $370.8M | $125.2M | ||
| Q4 24 | $337.5M | $149.7M | ||
| Q3 24 | $231.9M | $141.5M | ||
| Q2 24 | $492.5M | $126.7M | ||
| Q1 24 | $341.4M | $110.4M |
| Q4 25 | $67.4M | $1.7M | ||
| Q3 25 | $20.1M | $17.3M | ||
| Q2 25 | $7.9M | $-24.4M | ||
| Q1 25 | $284.0K | $-21.7M | ||
| Q4 24 | $45.1M | $14.7M | ||
| Q3 24 | $27.4M | $-6.7M | ||
| Q2 24 | $36.0M | $-15.7M | ||
| Q1 24 | $5.6M | $-48.4M |
| Q4 25 | 70.3% | 85.7% | ||
| Q3 25 | 57.8% | 88.5% | ||
| Q2 25 | 29.6% | 90.2% | ||
| Q1 25 | 41.2% | 90.7% | ||
| Q4 24 | 63.1% | 90.1% | ||
| Q3 24 | 76.4% | 90.6% | ||
| Q2 24 | 35.6% | 91.1% | ||
| Q1 24 | 37.6% | 87.7% |
| Q4 25 | 26.6% | 8.6% | ||
| Q3 25 | 8.7% | 20.3% | ||
| Q2 25 | 4.6% | -6.1% | ||
| Q1 25 | 0.9% | -6.3% | ||
| Q4 24 | 19.9% | 10.7% | ||
| Q3 24 | 26.8% | 15.3% | ||
| Q2 24 | 11.6% | 11.8% | ||
| Q1 24 | 4.1% | -25.1% |
| Q4 25 | 20.5% | 0.9% | ||
| Q3 25 | 6.8% | 10.2% | ||
| Q2 25 | 1.5% | -15.8% | ||
| Q1 25 | 0.1% | -17.3% | ||
| Q4 24 | 13.4% | 9.8% | ||
| Q3 24 | 11.8% | -4.8% | ||
| Q2 24 | 7.3% | -12.4% | ||
| Q1 24 | 1.6% | -43.9% |
| Q4 25 | — | $0.00 | ||
| Q3 25 | $0.59 | $0.06 | ||
| Q2 25 | $0.23 | $-0.08 | ||
| Q1 25 | $0.01 | $-0.07 | ||
| Q4 24 | $1.31 | $0.05 | ||
| Q3 24 | $0.80 | $-0.02 | ||
| Q2 24 | $1.05 | $-0.05 | ||
| Q1 24 | $0.16 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.3M | $293.5M |
| Total DebtLower is stronger | $560.0M | $392.7M |
| Stockholders' EquityBook value | $1.2B | $274.2M |
| Total Assets | $3.7B | $949.9M |
| Debt / EquityLower = less leverage | 0.45× | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $98.3M | $293.5M | ||
| Q3 25 | — | $263.8M | ||
| Q2 25 | — | $231.0M | ||
| Q1 25 | — | $250.6M | ||
| Q4 24 | $561.8M | $249.9M | ||
| Q3 24 | — | $249.8M | ||
| Q2 24 | — | $260.1M | ||
| Q1 24 | — | $239.6M |
| Q4 25 | $560.0M | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | $608.2M | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M | ||
| Q1 24 | — | $388.4M |
| Q4 25 | $1.2B | $274.2M | ||
| Q3 25 | $1.2B | $230.4M | ||
| Q2 25 | $1.4B | $204.3M | ||
| Q1 25 | $1.4B | $193.6M | ||
| Q4 24 | $1.4B | $194.0M | ||
| Q3 24 | $1.3B | $178.8M | ||
| Q2 24 | $1.3B | $132.5M | ||
| Q1 24 | $1.3B | $130.7M |
| Q4 25 | $3.7B | $949.9M | ||
| Q3 25 | $3.3B | $868.8M | ||
| Q2 25 | $3.4B | $815.3M | ||
| Q1 25 | $3.8B | $789.8M | ||
| Q4 24 | $4.1B | $785.0M | ||
| Q3 24 | $3.4B | $786.6M | ||
| Q2 24 | $3.3B | $749.5M | ||
| Q1 24 | $3.3B | $721.8M |
| Q4 25 | 0.45× | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | 0.45× | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× | ||
| Q1 24 | — | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.2M | $16.3M |
| Free Cash FlowOCF − Capex | $-77.1M | $16.0M |
| FCF MarginFCF / Revenue | -23.4% | 8.6% |
| Capex IntensityCapex / Revenue | 21.5% | 0.2% |
| Cash ConversionOCF / Net Profit | -0.09× | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | $-56.1M | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.2M | $16.3M | ||
| Q3 25 | $233.9M | $35.7M | ||
| Q2 25 | $299.3M | $-26.5M | ||
| Q1 25 | $-350.0M | $7.8M | ||
| Q4 24 | $268.8M | $-3.9M | ||
| Q3 24 | $-2.1M | $-23.0M | ||
| Q2 24 | $304.4M | $22.7M | ||
| Q1 24 | $-239.6M | $-29.7M |
| Q4 25 | $-77.1M | $16.0M | ||
| Q3 25 | $167.0M | $35.3M | ||
| Q2 25 | $250.5M | $-28.9M | ||
| Q1 25 | $-396.6M | $7.5M | ||
| Q4 24 | $212.9M | $-4.2M | ||
| Q3 24 | $-40.0M | $-23.3M | ||
| Q2 24 | $275.8M | $21.6M | ||
| Q1 24 | $-266.4M | $-31.5M |
| Q4 25 | -23.4% | 8.6% | ||
| Q3 25 | 56.5% | 20.9% | ||
| Q2 25 | 46.8% | -18.7% | ||
| Q1 25 | -106.9% | 6.0% | ||
| Q4 24 | 63.1% | -2.8% | ||
| Q3 24 | -17.2% | -16.5% | ||
| Q2 24 | 56.0% | 17.0% | ||
| Q1 24 | -78.0% | -28.5% |
| Q4 25 | 21.5% | 0.2% | ||
| Q3 25 | 22.6% | 0.2% | ||
| Q2 25 | 9.1% | 1.6% | ||
| Q1 25 | 12.6% | 0.2% | ||
| Q4 24 | 16.6% | 0.2% | ||
| Q3 24 | 16.3% | 0.3% | ||
| Q2 24 | 5.8% | 0.9% | ||
| Q1 24 | 7.8% | 1.6% |
| Q4 25 | -0.09× | 9.62× | ||
| Q3 25 | 11.61× | 2.06× | ||
| Q2 25 | 38.10× | — | ||
| Q1 25 | -1232.46× | — | ||
| Q4 24 | 5.96× | -0.27× | ||
| Q3 24 | -0.08× | — | ||
| Q2 24 | 8.46× | — | ||
| Q1 24 | -42.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
